ESH AL 2026 | How disease biology differs between younger and older patients with Ph-negative B-ALL
In this video, Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, briefly discusses the complexities of Ph-negative acute lymphoblastic leukemia (ALL), highlighting the varying biological characteristics and genetic drivers observed in adults with this subtype compared to pediatric patients. This interview took place at the 5th How to Diagnose and Treat: Acute Leukemias meeting of the European School of Hematology (ESH AL) in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Ph-negative B-ALL is a really interesting disease because it affects humans all over the age spectrum. This ALL, Ph-negative ALL in particular, has historically been considered a pediatric disease where the pediatricians, our pediatric oncology colleagues, really led the way in learning how to treat ALL. And us adult hematologist/oncologists adapted their regimens and essentially just modified pediatric regimens for adults...
Ph-negative B-ALL is a really interesting disease because it affects humans all over the age spectrum. This ALL, Ph-negative ALL in particular, has historically been considered a pediatric disease where the pediatricians, our pediatric oncology colleagues, really led the way in learning how to treat ALL. And us adult hematologist/oncologists adapted their regimens and essentially just modified pediatric regimens for adults. But ALL also, as I’m alluding to, affects younger adults, so-called middle-aged adults and adults who are in later years of life. And they have the same disease, but we know it’s not biologically the same. The genetic drivers of ALL in adults are varied and heterogeneous, but generally tend towards more resistant subtypes, less likely to respond to conventional chemotherapy and more likely to be resistant and in need of novel treatment approaches.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Research Funding to Institution: Novartis, AbbVie
Advisory Boards/Consulting: Jazz, Kite, Pfizer, Novartis, AbbVie, KITE, Syndax, Servier, Autolus, Astra Zeneca
